您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Alirocumab(anti-PCSK9)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Alirocumab(anti-PCSK9)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1245916-14-6
包装:1mg
市场价:7020元

产品介绍
Alirocumab (anti-PCSK9) 是一种 PCSK9 的人单克隆抗体。Alirocumab 特异性结合 PCSK9,PCSK9 是肝脏低密度脂蛋白 (LDL) 受体的下调剂,从而提高肝脏结合 LDL-胆固醇 (LDL-C) 的能力并降低血液中的 LDL-C 水平。Alirocumab 可用于高胆固醇血症的研究。
Cas No.1245916-14-6
别名阿利库单抗,REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
储存条件Store at 4℃, Do not freeze
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia[1][2].

[1]. Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705.
[2]. Tavori H, et al. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44.